Prospective evaluation of neuromediator dynamics in castration-resistant prostate cancer patients during docetaxel

• Verfasst von: Hardenberg, Jost von [VerfasserIn]
• Verfasst von: Schwartz, Maike [VerfasserIn]
• Verfasst von: Weiß, Christel [VerfasserIn]
• Titel: Prospective evaluation of neuromediator dynamics in castration-resistant prostate cancer patients during docetaxel
• Verf.angabe: Jost von Hardenberg, Maike Schwartz, Thorsten Werner, Stefan Fuxius, Markus Müller, Thomas Frangenheim, Christian Bolenz, Christel Weiss and Elmar Heinrich
• E-Jahr: 2017
• Jahr: September 2017
• Umfang: 8 S.
• Fussnoten: Gesehen am 08.10.2018
• Titel Quelle: Enthalten in: Anticancer research
• Ort Quelle: Kapandriti, Attiki, Greece : International Institute of Anticancer Research, 2004
• Jahr Quelle: 2017
• Band/Heft Quelle: 37(2017), 9, Seite 5117-5124
• ISSN Quelle: 1791-7530
• DOI: doi:10.21873/anticanres.11931
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1581636725

Abstract

Aim: Aim of the study was to detect small cell/neuroendocrine (SCNC) transformation in metastatic castration-resistant prostate cancer (mCRPC) that is a challenging procedure. We investigated the role of neuromediator dynamics as potential evidence of SCNC in patients undergoing docetaxel therapy. Patients and Methods: A multi-institutional, prospective observational study was conducted. Patients undergoing docetaxel treatment were included. Chromogranin A (CGA), neuron-specific enolase (NSE), and pro-gastrin releasing peptide (Pro-GRP) were sequentially evaluated at predefined time points. Outcome measures were overall survival (OS), progression-free survival (PFS) and PSA nadir. Results: Fifty-two patients were included. A general rise in CGA levels was observed. Patients with a high CGA rise (100%ULN: CGA ≥98.1ng/ml) between the 1st and 3rd cycle trended towards a decreased OS (p=0.0649) and showed a decreased PFS (p=0.0369). In multivariate analysis, continuous CGA rise correlated with PFS (p=0.0553; HR 1.136), but was not an independent predictor of OS. Conclusion: Patients with an early high CGA rise may demonstrate a subgroup with poor outcome due to underlying SCNC transformation. Monitoring of CGA appears to be an option worth considering.